title: Potential role of interleukin-1 in the development of bronchopulmonary dysplasia.
abstract: Increased activities of inflammatory mediators unopposed by their inhibitors contribute to chronic lung injury and impaired healing in BPD. The deleterious effects of IL-1 beta, a cytokine involved in inflammation and host defense, are blocked by IL-1 receptor antagonist (IL-1Ra). We proposed that an imbalance of IL-1 beta and its inhibitors may contribute to the development of BPD. To determine the relative antigen concentrations of IL-1 beta and IL-1Ra and functional IL-1 activity in lung lavage of infants at risk for BPD, lung lavage was serially obtained from 1 to 28 days from 17 infants with evolving BPD, 13 infants with self-limited RDS, and 6 controls ventilated for nonpulmonary reasons. Overall, there was a high correlation between IL-1 beta antigen concentration and IL-1 activity (r = 0.82, p = 0.0001). There were no significant differences among the groups for lung lavage variables on day 1. However, in infants who developed BPD, IL-1 beta antigen concentration and IL-1 activity increased 16- and 61-fold, respectively, during the first week. IL-1Ra remained relatively unchanged during the first month. IL-1 beta/IL-1Ra antigen ratio was significantly higher on days 5 (median 0.024) and 7 (median 0.025) compared with day 1 (median 0.004), p < 0.05. These results suggest that a relative imbalance of IL-1 beta and IL-1Ra may contribute to prolonged inflammation in BPD.
authors.affiliation: Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Rindfleisch
authors.forename: J D
authors.initials: JD
authors.lastname: Hasday
authors.forename: V
authors.initials: V
authors.lastname: Taciak
authors.forename: K
authors.initials: K
authors.lastname: Broderick
authors.forename: R M
authors.initials: RM
authors.lastname: Viscardi
mesh_terms: D001992:Bronchoalveolar Lavage Fluid; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology*; D008297:Male; D011994:Recombinant Proteins / Q000494:pharmacology; D012795:Sialoglycoproteins / Q000276:immunology / Q000494:pharmacology*
chemical_list: C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D011994:Recombinant Proteins; D012795:Sialoglycoproteins